Effect of myoinositol plus metformin versus metformin alone on high serum AMH level in infertile PCOS women: clinical and biochemical response

Munmun Islam; Abu Shaleh M. Mohiuddin Sirazi; Humaira Alam; Suraiya Jahan Rolly; Rebeka Sultana; Mostafa M. Al Tarique; Khan Shihan Mahmud; Jesmine Banu

doi:10.18203/2320-1770.ijrcog20252714

Authors

Munmun Islam Department of Reproductive Endocrinology and Infertility, Directorate General of Health Services (DGHS), Mohakhali, Dhaka, Bangladesh
Abu Shaleh M. Mohiuddin Sirazi Department of Anaestehsia, Analgesia, Palliative and Intensive Care, Dhaka Medical College Hospital, Dhaka, Bangladesh
Humaira Alam Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University, Dhaka, Bangladesh
Suraiya Jahan Rolly Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University, Dhaka, Bangladesh
Rebeka Sultana Department of Reproductive Endocrinology and Infertility, Directorate General of Health Services (DGHS), Mohakhali, Dhaka, Bangladesh
Mostafa M. Al Tarique Department of Reproductive Endocrinology and Infertility, Directorate General of Health Services (DGHS), Mohakhali, Dhaka, Bangladesh
Khan Shihan Mahmud Department of Pediatrics, 250 Bed District Hospital, Bagerhat, Bangladesh
Jesmine Banu Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20252714

Keywords:

Anti-Müllerian hormone, Myoinositol and metformin, Polycystic ovary syndrome

Abstract

Background: Polycystic ovary syndrome (PCOS), a common endocrine disorder in reproductive-age women, is characterized by insulin resistance, hyperandrogenism, and elevated serum AMH levels. Both metformin and myoinositol improve insulin sensitivity through different mechanisms, potentially enhancing reproductive outcomes. This study aimed to compare the clinical and biochemical effects of combined myoinositol and metformin therapy versus metformin alone in reducing high serum AMH levels in infertile PCOS women.

Methods: This randomized controlled trial at BSMMU’s department of reproductive endocrinology and infertility (July 2022-June 2023) randomized 80 PCOS women (18-35 years) to myoinositol+metformin (n=40) or metformin alone (n=40) for 3 months. We assessed AMH (primary outcome), BMI, waist-hip ratio, menstrual regularity, hormones (LH/testosterone), glucose metabolism, and pregnancy rates, analyzed via SPSS 23 (t-tests; p<0.05 significant).

Results: In 80 subfertile PCOS women (40/group), myoinositol+metformin (group A) outperformed metformin alone (group B): greater reductions in BMI (27.1 to 24.5 versus 27.4 to 25.3), waist-hip ratio (0.91 to 0.86 versus 0.90 to 0.88), AMH (12.2 to 9.5 versus 12.3 to 8.6 ng/ml), LH (10.1 to 6.4 versus 9.9 to 6.9 mIU/ml), and testosterone (2.1 to 1.4 versus 2.3 to 1.7 ng/ml). Group A showed higher menstrual regularity (95% versus 87.2%) and pregnancy rates (10% versus 5.1%).

Conclusions: Combination therapy of myoinositol and metformin is more effective than metformin alone in improving clinical and biochemical outcomes in infertile PCOS women.

Metrics

Metrics Loading ...

References

Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370(9588):685-97. DOI: https://doi.org/10.1016/S0140-6736(07)61345-2

Franks S. Polycystic ovary syndrome in adolescents. Int J Obes. 2008;32(7):1035-41. DOI: https://doi.org/10.1038/ijo.2008.61

Zhao Y, Qiao J. Ethnic differences in the phenotypic expression of polycystic ovary syndrome. Steroids. 2013;78(8):755-60. DOI: https://doi.org/10.1016/j.steroids.2013.04.006

Orio F, Palomba S. New guidelines for the diagnosis and treatment of PCOS. Nat Rev Endocrinol. 2014;10(3):130-2. DOI: https://doi.org/10.1038/nrendo.2013.248

Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic ovary syndrome. Am Fam Phys. 2016;94(2):106-13.

Baillargeon JP, Nestler JE. Polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab. 2006;91(1):22-4. DOI: https://doi.org/10.1210/jc.2005-1804

Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Müllerian hormone in women. Hum Reprod Update. 2014;20(3):370-85. DOI: https://doi.org/10.1093/humupd/dmt062

Mumford SL, Legro RS, Diamond MP, Coutifaris C, Steiner AZ, Schlaff WD, et al. Baseline AMH level associated with ovulation following ovulation induction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2016;101(9):3288-96. DOI: https://doi.org/10.1210/jc.2016-1340

Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti‐Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10(2):77-83. DOI: https://doi.org/10.1093/molehr/gah015

Knight PG, Glister C. TGF-β superfamily members and ovarian follicle development. Reproduction. 2006;132(2):191-206. DOI: https://doi.org/10.1530/rep.1.01074

La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. Anti-Müllerian hormone (AMH): what do we still need to know? Hum Reprod. 2009;24(9):2264-75. DOI: https://doi.org/10.1093/humrep/dep210

Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88(12):5957-62. DOI: https://doi.org/10.1210/jc.2003-030727

Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89(1):318-23. DOI: https://doi.org/10.1210/jc.2003-030932

Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20(7):1820-6. DOI: https://doi.org/10.1093/humrep/deh850

Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz DJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril. 2002;77(2):209-15. DOI: https://doi.org/10.1016/S0015-0282(01)02963-6

Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, et al. Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril. 2005;83(1):130-6. DOI: https://doi.org/10.1016/j.fertnstert.2004.05.098

Neagu M, Cristescu C. Anti-Műllerian hormone- a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome. J Med Life. 2012;5(4):462.

Foroozanfard F, Samimi M, Almadani KH, Sehat M. Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome. Electron Phys. 2017;9(12):5969.

Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011;15(8):931-6.

Does Inositol Boost AMH and Fertility? London Acupuncture Space. 2023. Available from: https://acupuncturespace.com/does-inositol-boosts-amh-and-fertility/. Accessed on 3 May 2025.

Rani C, Deeba F, Ishrat S, Banu J, Jahan S, Nazneen S, et al. Effects of metformin plus myo-inositol compared to metformin alone as pre-treatment of ovulation induction in polycystic ovary syndrome with insulin resistance. Int J Reprod Contracept Obstet Gynecol. 2022;11(11):3006.

Liu Z, Song Y, Xu Y, Wang J, Hu H, Weng Y. The comparison of the effectiveness and safety of drospirone ethinyl estradiol and ethinyl estradiol cyproterone in the treatment of polycystic ovarian syndrome: a protocol for systematic review and meta-analysis. Medicine. 2020;99(51):e23811. DOI: https://doi.org/10.1097/MD.0000000000023811

Rani M, Singh MA. Study on the efficacy and safety of Myoinositol and Metformin in the treatment of PCOS. J Med Sci Clin Res. 2019;7(5):712-6. DOI: https://doi.org/10.18535/jmscr/v7i5.115

Rani C, Deeba F, Ishrat S, Banu J, Jahan S, Nazneen S, et al. Effects of metformin plus myo-inositol compared to metformin alone as pre-treatment of ovulation induction in polycystic ovary syndrome with insulin resistance. Int J Reprod Contracept Obstet Gynecol. 2022;11(11):3006. DOI: https://doi.org/10.18203/2320-1770.ijrcog20222785

Agrawal A, Mahey R, Kachhawa G, Khadgawat R, Vanamail P, Kriplani A. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol Endocrinol. 2019;35(6):511-4. DOI: https://doi.org/10.1080/09513590.2018.1549656

Gade P, Sharmeen V. Myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles: a comparative study. Int J Clin Biomed Res. 2021:6-10. DOI: https://doi.org/10.31878/ijcbr.2021.72.02

Ravn P, Gram F, Andersen MS, Glintborg D. Myoinositol versus metformin in women with polycystic ovary syndrome: a randomized controlled clinical trial. Metabolites. 2022;12(12):1183. DOI: https://doi.org/10.3390/metabo12121183

Chhabra N, Malik S. Effect of insulin sensitizers on raised serum anti-mullerian hormone levels in infertile women with polycystic ovarian syndrome. J Hum Reprod Sci. 2018;11(4):348-52. DOI: https://doi.org/10.4103/jhrs.JHRS_59_17

Foroozanfard F, Samimi M, Almadani KH, Sehat M. Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome. Electron Phys. 2017;9(12):5969. DOI: https://doi.org/10.19082/5969